Skip to main
BLCO

BLCO Stock Forecast & Price Target

BLCO Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 8%
Buy 33%
Hold 50%
Sell 8%
Strong Sell 0%

Bulls say

Bausch & Lomb has raised its 2025 revenue guidance to a range of $5,050-5,150 million, indicating a consistent growth forecast of 5-7% in constant currency. The company is projected to achieve an adjusted EBITDA between $860-910 million, highlighting operational efficiency and financial health. Key product lines, such as MIEBO and XIIDRA, have shown significant year-over-year prescription growth, underscoring the strength of Bausch & Lomb's diverse portfolio and market position in the vision care sector.

Bears say

Bausch & Lomb’s financial outlook presents several concerns that contribute to a negative assessment of the stock. Despite reporting revenue growth in its Vision Care and Surgical segments, the Pharmaceuticals segment showed a slight decline, and persistent pricing pressure on key products like XIIDRA raises concerns about future revenue stability. Additionally, the company's high debt levels resulting from its acquisition of XIIDRA, coupled with a limited product pipeline and competitive pressures, further threaten its long-term growth prospects.

BLCO has been analyzed by 12 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bausch + Lomb Corp (BLCO) Forecast

Analysts have given BLCO a Hold based on their latest research and market trends.

According to 12 analysts, BLCO has a Hold consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bausch + Lomb Corp (BLCO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.